65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01075438 (ClinicalTrials.gov) | March 2010 | 24/2/2010 | Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients | Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients | Ataxia Telangiectasia | Biological: Prevenar® (7-valent pneumococcal conjugate vaccine);Biological: Pneumovax® (pneumococcal polysaccharide vaccine) | Sheba Medical Center | NULL | Not yet recruiting | 2 Years | 25 Years | Both | 20 | N/A | Israel |
| 2 | EUCTR2007-003235-23-FR (EUCTR) | 09/01/2009 | 23/10/2008 | Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type prime boost associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie de l'injection du vaccin polysaccharidique à S4 comparé à l'administration du vaccin polysaccharidique seul à S4 chez des patients ayant un déficit immunitaire commun variable - Evaluation d'une stratégie vaccinale anti-pneumococcique chez des patients aynt un DICV | Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type prime boost associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie de l'injection du vaccin polysaccharidique à S4 comparé à l'administration du vaccin polysaccharidique seul à S4 chez des patients ayant un déficit immunitaire commun variable - Evaluation d'une stratégie vaccinale anti-pneumococcique chez des patients aynt un DICV | Déficit immunitaire commun variable MedDRA version: 9.1;Level: LLT;Classification code 10010112;Term: Common variable immunodeficiency | Trade Name: PNEUMO 23 Trade Name: PREVENAR | Inserm | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | France | |||
| 3 | NCT00656409 (ClinicalTrials.gov) | June 2006 | 7/4/2008 | Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) | Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) | Ataxia Telangiectasia (AT) | Drug: Conjugated pneumococcal vaccine (Prevenar) | Institute of Child Health | Great Ormond Street Hospital for Children NHS Foundation Trust | Completed | 2 Years | N/A | Both | 30 | Phase 3 | United Kingdom |
| 4 | EUCTR2005-004122-70-GB (EUCTR) | 15/11/2005 | 12/09/2005 | Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia | Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia | Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections. | Trade Name: Prevenar | Great Ormond Street Hospital | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |